1. Community-acquired pneumonia: How far have we come?

   • Gerald R. Donowitz

   Invited Commentary Pages: 419 - 420

2. Web alert

   News Pages: 421 - 422

3. Adjunctive immunotherapy in combination with lipid-associated amphotericin B for the treatment of invasive candidiasis

   • Stanley W. Chapman

   Clinical Trials Report Pages: 425 - 426

4. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia

   • Jack D. Sobel

   OriginalPaper Pages: 427 - 433

5. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient

   • Arlo Upton
   • Kieren A. Marr

   OriginalPaper Pages: 434 - 441

6. The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and candida

   • Thomas F. Patterson

   OriginalPaper Pages: 442 - 448

7. Recent insights into the mechanisms of antifungal resistance

   • Katherine S. Barker
   • P. David Rogers

   OriginalPaper Pages: 449 - 456

8. Stress, bacterial vaginosis, and the role of immune processes

   • Jennifer F. Culhane
   • Virginia A. Rauh
   • Robert L. Goldenberg

   OriginalPaper Pages: 459 - 464

9. Urinary tract infection in women: New pathogenic considerations

   • Ann E. Stapleton

   OriginalPaper Pages: 465 - 472

10. Vulvar vestibulitis syndrome

    • Carolyn Gardella

    OriginalPaper Pages: 473 - 480

11. Management of recurrent vulvovaginal candidiasis: Unresolved issues

    • Jack D. Sobel

    OriginalPaper Pages: 481 - 486

12. Novel antiretroviral agents in HIV therapy

    • Caitlin Reed
    • Eric S. Daar

    OriginalPaper Pages: 489 - 496

13. Metabolic abnormalities in HIV-infected patients: An update

    • Todd T. Brown
    • Joseph Cofrancesco Jr

    OriginalPaper Pages: 497 - 504